Friday, October 16, 2026

Back to today

From X

@convequity 1 click

Convequity on X

Convequity’s AI Bubble Barometer (ABBX) — Week of 2 October 2026 Our weekly framework tracks valuations, returns, capex, financing risk and infrastructure capacity across hyperscalers, neoclouds and model labs. Friday 2 Oct 2026 close (US ET): - Price drove the move: EV rose about $44B to about $14,114B. Invested capital (IC) was unchanged at $2,338B. - EV/IC: 6.04x, up 0.02x from 6.02x on 25 Sep. - All-in EV/IC: 6.76x. 1. Returns. Our paired, annualized forward ROIC (which is not trailing accounting ROIC) for Q2 2026 is 30.0%, against an AI WACC of 9.8%: 3.07x ROIC/WACC and a spread of +20.3 percentage points. 2. Capex. Latest-quarter cash capex is $228.7B. 3. Debt. Borrowings are $595B. All-in exposure is $3,624B, or 6.10x borrowings, adding purchase obligations, construction commitments and uncommenced leases on top of borrowings and leases. 4. Gigawatts. Current capacity is 45.7 GW, with 153.4 GW planned. $MSFT versus $GOOGL: MSFT’s all-in exposure is about 17x borrowings, and it is renting more: external capacity is about 12% now and 21% of planned capacity. GOOGL’s all-in exposure is 10.2x borrowings, while its external capacity share remains small at about 4% now. We see a price-led rise in valuation, with modeled forward returns still well above the cost of capital. Future spending commitments are much larger than borrowings alone suggest, and the reliance on rented capacity differs across companies.
@StableBread

Fajasy on X

My investing thesis in a nutshell (w/examples): 1) Buy with a strong margin of safety or stock price near/below cash and/or book value. 2) Buy in industries and/or markets where the money is flowing. Makes it a lot easier. 3) Buy the best early and/or the most overlooked in that particular industry. 4) Pay up for unfair advantages, excellent mgmt teams, and companies with huge latent pricing power. 5) Sell when the thesis breaks. Or a much better risk/reward setup hits your desk. Otherwise continue to add/hold. Don't track stock prices. Track the main business KPIs like any competent mgmt team would. Example #1: Bought $NBIS 4x mid $20's (best overall). Then bought $BRUN common and warrants pre-merger (most overlooked). Example #2: Bought $FTEK $1.39. Cash floor new excellent operator CEO. Strong upside potential w/data centers. Example #3: Bought $BABA $70's. Strong margin of safety, market leader, unfair advantages. Sold $170 for better risk/reward. Example #4: Bought $ELMT @$19 and @$14. Unfair advantage. Strategic. Cheap. Critical in strong growth industries. Example #5: Bought $TOST @$24. Beaten down due to macro headwinds and new/early $DASH competition. But almost everything in business stronger and expanding to new verticals. Lastly, if you're unsure or don't fully understand the business. Just say no. In fact, say no to most stocks. Most probably your best idea is already in your portfolio. Don't lockup your money in a 3/5 setup, you're trying to make outsized returns! And sub to my newsletter (link in bio) if you want my deep dives. 😉

2026.42: Home At Last

Stratechery’s weekly bundle covers Apple HomeView and SpaceX’s cellular ambitions.

TSOH Weekly Roundup (10/16/2026)

Bumble agreed to a $1.3 billion take-private deal, while Netflix cut about 1,000 jobs and Meta discussed its Muse superintelligence models.

Is The Market Turning The Page?

CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.

PesoRama: Research Flash

PesoRama will reach 54 JOi Dollar Plus stores by November after raising C$28.4 million, funding more than 50 additional Mexican store…

Modine Deep Dive

Modine, soon Modexus Solutions, has a $4 billion hyperscaler cooling contract but must ramp factory output and restore margins as data…

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…

LLY · long

LILLY (ELI) & CO

Eli Lilly trades at 33 times this year’s earnings and 26 times next year’s, versus roughly 12 times for big pharma peers.

Constellation: Stars Aligning?

Constellation Brands trades near $127 at roughly 11x next-twelve-month EV/EBIT, with recent business results offsetting concerns over…

TSMC Q3 FY12/26 Earnings Review

TSMC reported excellent Q3 results, guided Q4 revenue growth higher and saw its shares slip despite strong AI-driven earnings momentum.

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 108

X accounts we follow

Every account on this site, hand-picked.

89 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.